clinical trial · NCT06596876
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Jiangsu HengRui Medicine Co., Ltd.·phase3·completed·n = 165
Parkinson's DiseaseHRG2010; Sustained-release Carbidopa/Levodopa administered placeboSustained-release Carbidopa/Levodopa; HRG2010 placebo
brief summary
The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.
started
Nov 6, 2024
primary completion
Oct 9, 2025
completion
Jan 29, 2026
last updated
Jun 8, 2026
official title
A Randomized, Controlled, Double-blind, Double-dummy, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol